Supplies are limited till mid-November 2024. Actions and guidance are as provided in National Patient Safety Alert (NatPSA/2024/012/DHSC) issued on 25th October
Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
A licensed generic liposomal amphotericin B (Tillomed) is available. Learn about key differences compared to AmBisome Liposomal amphotericin B (Gilead) brand.
Intravenous thiamine for prevention of refeeding syndrome should be reserved for those with intestinal failure where the oral or enteral route is unavailable.
The availability of pancreatic enzyme replacement therapies (PERTs) varies currently. Use our resources and mini-tool to find matches for licensed products.
The availability of medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD) varies currently. Supply content is maintained regularly by DHSC.
Delegation of any PGD function is not permitted. However there are specific tasks that individuals other than the professional working under a PGD can fulfil.
Understanding when PGDs are a suitable mechanism for the supply and/or administration of medicines ensures an appropriate legal framework for service provision.
Understanding when PGDs are an unsuitable mechanism for the supply and/or administration of medicines ensures an alternative legal framework is applied.
Understanding where PGDs can and cannot be used for the supply and/or administration of P and GSL medicines helps ensure correct legal mechanisms in practice.
Continue breastfeeding during COVID-19 infection, even if dexamethasone, Paxlovid, sotrovimab or tocilzumab are required. COVID-19 vaccines can also be given.
If you're a healthcare professional who needs further advice, get in touch with us. You can contact us through our single email or telephone number below. Please don't share patient identifiable data with us by email.
Practical guidance to ensure opportunities to learn from local intelligence, including patient harm are translated into shared local and national learning
Healthcare professionals delivering the medication safety agenda in their organisation require an understanding of national policy, frameworks and legislation
Effective use provides assurance that an organisation is aware of the most critical medication safety related information, and acts on this to improve safety
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.